Chondrogenesis Marker Antibody Panel Reference: ARG30314 Chondrogenesis Marker antibody; CDKN2A / p16INK4a antibody; CD44 antibody; FOXC2 antibody; FOXC1 antibody
Interleukin-33 Monoclonal Antibody (Clone IL333068A) Reference: 10810-50 Antigen: recombinant human IL-33 • Host: mouse, clone IL333068A • Cross Reactivity: (+) human IL-33 • Application(s): ELISA and WB • IL-33, a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis.
Valanafusp alfa Reference: HY-P99530 Valanafusp alfa (AGT-181) is a brain penetrating recombinant fusion protein of a chimeric monoclonal antibody against the human insulin receptor (HIR) and human iduronidase (IDUA). Valanafusp alfa can be used for the research of Mucopolysaccharidosis type I (MPS I) .
Interleukin-33 Monoclonal Antibody (Clone IL33026B) Reference: 10811-100 Antigen: recombinant human IL-33 • Host: mouse, clone IL33026B • Cross Reactivity: (+) human and mouse IL-33 • Application(s): ELISA, IP, and WB • IL-33, a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis.
Polatuzumab Reference: HY-P99042 Polatuzumab is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab can be used to synthesize Polatuzumab Vedotin, which is an antibody-drug conjugate (ADC) targeting CD79b .
Interleukin-33 Monoclonal Antibody (Clone IL33026B) Reference: 10811-50 Antigen: recombinant human IL-33 • Host: mouse, clone IL33026B • Cross Reactivity: (+) human and mouse IL-33 • Application(s): ELISA, IP, and WB • IL-33, a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis.
Adebrelimab Reference: HY-P99422 Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC).